Table 1 Baseline characteristics of patients included in this study
Characteristics | Whole cohort (n = 126) | Ischemic stroke (n = 60) | Non-ischaemic stroke (n = 66) | P-value |
|---|---|---|---|---|
Age (years) | 71.4 (60.6–79.1) | 72.1 (60.7–80.5) | 69.2 (60.3–77.9) | 0.387 |
Male sex | 71 (56.3%) | 36 (60.0%) | 35 (53.0%) | 0.475 |
BMI | 28.1 (24.9–31.0) [3] | 28.6 (25.3–32.0) | 27.8 (24.5–30.5) [3] | 0.297 |
Hours from symptom onset to presentation | 2.6 (1.2–4.6) [14] | 2.6 (1.3–5.0) [5] | 2.6 (1.1–4.3) [9] | 0.481 |
Smoking history | ||||
 Never smoked | 49 (38.9%) | 20 (33.3%) | 29 (43.9%) | 0.449 |
 Ex-smoker | 54 (42.9%) | 27 (45.0%) | 27 (40.9%) | |
 Current smoker | 23 (18.3%) | 13 (21.7%) | 10 (15.2%) | |
Comorbidities | ||||
 Hypertension | 87 (69.0%) | 42 (70.0%) | 45 (68.2%) | 0.849 |
 CHD | 42 (33.3%) | 21 (35.0%) | 21 (31.8%) | 0.710 |
 TIA | 42 (33.3%) | 16 (26.7%) | 26 (39.4%) | 0.185 |
 Stroke | 51 (40.5%) | 34 (56.7%) | 17 (25.8%) |  < 0.001 |
 Diabetes | 29 (23.0%) | 15 (25.0%) | 14 (21.2%) | 0.675 |
Prescription for | ||||
 Aspirin | 36 (28.6%) | 14 (23.3%) | 22 (33.3%) | 0.241 |
 Other antiplatelet drugs | 10 (7.9%) | 5 (8.3%) | 5 (7.6%) | 1.000 |
 Anticoagulants | 19 (15.1%) | 8 (13.3%) | 11 (16.7%) | 0.628 |
 Calcium channel blockers | 27 (21.4%) | 10 (16.7%) | 17 (25.8%) | 0.278 |
 Beta-blockers | 31 (24.6%) | 13 (21.7%) | 18 (27.3%) | 0.537 |
 ACE inhibitors | 25 (19.8%) | 14 (23.3%) | 11 (16.7%) | 0.379 |
 ARBs | 36 (28.6%) | 14 (23.3%) | 22 (33.3%) | 0.241 |
 Statins | 53 (42.1%) | 22 (36.7%) | 31 (47.0%) | 0.281 |
 Metformin | 13 (10.3%) | 6 (10.0%) | 7 (10.6%) | 1.000 |
 Insulin | 5 (4.0%) | 2 (3.3%) | 3 (4.5%) | 1.000 |